Last reviewed · How we verify
ATRA+Chemo
ATRA (all-trans retinoic acid) combined with chemotherapy induces differentiation of leukemic blasts and enhances chemotherapy cytotoxicity in acute promyelocytic leukemia.
ATRA (all-trans retinoic acid) combined with chemotherapy induces differentiation of leukemic blasts and enhances chemotherapy cytotoxicity in acute promyelocytic leukemia. Used for Acute promyelocytic leukemia (APL).
At a glance
| Generic name | ATRA+Chemo |
|---|---|
| Also known as | retinoic acid + idarubicin or daunorubicin +/- Cytarabine |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Retinoid + chemotherapy combination |
| Target | Retinoic acid receptor (RAR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
ATRA binds to retinoic acid receptors and promotes terminal differentiation of abnormal promyelocytes, converting them from a proliferative to a non-proliferative state. When combined with chemotherapy agents, this differentiation therapy synergizes with cytotoxic chemotherapy to achieve high remission rates. This combination approach has become the standard of care for acute promyelocytic leukemia (APL), particularly in t(15;17) PML-RARA positive disease.
Approved indications
- Acute promyelocytic leukemia (APL), t(15;17) positive
Common side effects
- Differentiation syndrome (APL syndrome)
- Myelosuppression
- Hepatotoxicity
- Hypertriglyceridemia
- Chemotherapy-related toxicity (nausea, infection, bleeding)
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) (PHASE1, PHASE2)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma (PHASE2)
- Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (PHASE3)
- Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (PHASE1)
- A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma (PHASE2)
- ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATRA+Chemo CI brief — competitive landscape report
- ATRA+Chemo updates RSS · CI watch RSS
- Shanghai Jiao Tong University School of Medicine portfolio CI